CTOS 2023 | Elucidating novel biomarkers in osteosarcoma and Ewing sarcoma

Odion Binitie, MD, Moffitt Cancer Center, Tampa, FL, comments on biomarker research for sarcomas. Currently, histological response and preoperative imaging are the main biomarkers used, and potential biomarkers include circulating tumor DNA (ctDNA) and STAG2. Novel biomarkers will subsequently be able to drive drug development and monitor patient progress, such as in trials assessing cabozantinib in sarcoma. This interview took place at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting in Dublin, Ireland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.